(CercleFinance.com) – Inventiva announces the selection of an abstract on its Lanifibranor, for a presentation in plenary session at the third International Conference on Fatty Liver to be held from April 28 to 30, 2022 in Vienna, Austria.
This abstract focuses on the improvement of markers of cardiometabolic health in patients with NASH (non-alcoholic steatohepatitis) treated with Lanifibranor compared to placebo treatment.
‘In Inventiva’s Phase IIb NATIVE clinical study, lanifibranor demonstrated beneficial effects on liver histology, resolution of NASH and improvement of fibrosis in patients with NASH’, says the biopharmaceutical company. .
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.